-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a --

-- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

-- Initial clinical data expected in 2027 --

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD). With the IND cleared, PM577a may proceed to clinical study in the United States. Together with the Company’s previously announced New Zealand Clinical Trial Application (CTA) clearance, the IND clearance establishes a global Phase 1/2 program and opens participation to patients in the United States, where H1069Q is the single most common pathogenic variant causing WD.